S&P 500   3,357.75 (-0.66%)
DOW   29,138.73 (-0.88%)
QQQ   233.68 (-0.41%)
AAPL   317.12 (-2.41%)
FB   216.38 (+1.03%)
MSFT   186.78 (+0.77%)
GOOGL   1,516.20 (-0.17%)
AMZN   2,137.26 (+0.11%)
CGC   22.17 (+0.18%)
NVDA   290.84 (+0.36%)
BABA   217.79 (-0.84%)
MU   57.40 (-1.88%)
GE   12.79 (-0.31%)
TSLA   845.11 (+5.63%)
AMD   56.57 (+2.28%)
T   38.18 (-0.18%)
ACB   1.59 (+0.00%)
F   8.05 (-0.62%)
PRI   135.19 (-1.21%)
BAC   34.09 (-2.18%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.58%)
S&P 500   3,357.75 (-0.66%)
DOW   29,138.73 (-0.88%)
QQQ   233.68 (-0.41%)
AAPL   317.12 (-2.41%)
FB   216.38 (+1.03%)
MSFT   186.78 (+0.77%)
GOOGL   1,516.20 (-0.17%)
AMZN   2,137.26 (+0.11%)
CGC   22.17 (+0.18%)
NVDA   290.84 (+0.36%)
BABA   217.79 (-0.84%)
MU   57.40 (-1.88%)
GE   12.79 (-0.31%)
TSLA   845.11 (+5.63%)
AMD   56.57 (+2.28%)
T   38.18 (-0.18%)
ACB   1.59 (+0.00%)
F   8.05 (-0.62%)
PRI   135.19 (-1.21%)
BAC   34.09 (-2.18%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.58%)
S&P 500   3,357.75 (-0.66%)
DOW   29,138.73 (-0.88%)
QQQ   233.68 (-0.41%)
AAPL   317.12 (-2.41%)
FB   216.38 (+1.03%)
MSFT   186.78 (+0.77%)
GOOGL   1,516.20 (-0.17%)
AMZN   2,137.26 (+0.11%)
CGC   22.17 (+0.18%)
NVDA   290.84 (+0.36%)
BABA   217.79 (-0.84%)
MU   57.40 (-1.88%)
GE   12.79 (-0.31%)
TSLA   845.11 (+5.63%)
AMD   56.57 (+2.28%)
T   38.18 (-0.18%)
ACB   1.59 (+0.00%)
F   8.05 (-0.62%)
PRI   135.19 (-1.21%)
BAC   34.09 (-2.18%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.58%)
S&P 500   3,357.75 (-0.66%)
DOW   29,138.73 (-0.88%)
QQQ   233.68 (-0.41%)
AAPL   317.12 (-2.41%)
FB   216.38 (+1.03%)
MSFT   186.78 (+0.77%)
GOOGL   1,516.20 (-0.17%)
AMZN   2,137.26 (+0.11%)
CGC   22.17 (+0.18%)
NVDA   290.84 (+0.36%)
BABA   217.79 (-0.84%)
MU   57.40 (-1.88%)
GE   12.79 (-0.31%)
TSLA   845.11 (+5.63%)
AMD   56.57 (+2.28%)
T   38.18 (-0.18%)
ACB   1.59 (+0.00%)
F   8.05 (-0.62%)
PRI   135.19 (-1.21%)
BAC   34.09 (-2.18%)
DIS   138.39 (-0.82%)
GILD   67.18 (-0.58%)
Log in

NASDAQ:DEPO - Depomed Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume940,193 shs
Average Volume1.30 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Depomed, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:DEPO
CUSIP24990810
Phone510-744-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.


Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) issued its earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to the consensus estimate of $63.72 million. The company's revenue was down 37.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.08 EPS. View Depomed's Earnings History.

Has Depomed been receiving favorable news coverage?

Headlines about DEPO stock have trended neutral recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Depomed earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Depomed.

Who are some of Depomed's key competitors?

What other stocks do shareholders of Depomed own?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
  • Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

What is Depomed's official website?

The official website for Depomed is http://www.depomedinc.com/.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]


MarketBeat Community Rating for Depomed (NASDAQ DEPO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  493 (Vote Outperform)
Underperform Votes:  409 (Vote Underperform)
Total Votes:  902
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel